Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin, plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma.
George T, Ivey A, Daily K, Dang L, Watson S, Granicz R, Tormes K, Lu X, Liu C, Allegra C, Behrns K, Hughes S, Ogunwobi O, Trevino J. Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin, plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 319-319. DOI: 10.1200/jco.2014.32.3_suppl.319.Peer-Reviewed Original ResearchMetastatic pancreatic cancerProgression-free survivalGrade 3 AEsOverall survivalOral multi-tyrosine kinase inhibitorMedian progression-free survivalMulti-tyrosine kinase inhibitorSrc inhibitionAdequate organ functionBiochemical response rateECOG PS 0Grade 4 AEsGrade 5 toxicityRECIST measurable diseaseTriplet combination therapyPhase II studyMetastatic pancreatic adenocarcinomaClinical unmet needPredictors of responseQuality of lifeEligible ptsMFOLFOX6 chemotherapyMeasurable diseasePrior therapySecondary endpoints